Skip to main content
See every side of every news story
Published • loading... • Updated

Anika Therapeutics' (ANIK) "Buy" Rating Reiterated at B. Riley Financial

Summary by MarketBeat
B. Riley Financial reissued a "buy" rating and set a $17.00 price objective (down from $23.00) on shares of Anika Therapeutics in a research note on Monday.

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Monday, November 16, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal